�Biocompatibles is pleased to announce the headline results from the PRECISION V clinical tryout. A more complete presentation of the results will take place as planned at CIRSE (Cardiovascular and Interventional Radiological Society of Europe) 2008, September 13-17, 2008, Copenhagen. A further announcement testament be made at that time.
PRECISION V is a prospective, single subterfuge, Phase II randomised controlled trial evaluating Biocompatibles' Drug-Eluting Bead against a control arm of conventional TACE (cTACE) in HCC. 212 patients were recruited at 23 European hospitals. 201 patients received at least one treatment and ar the footing for this primary analysis.
The Principal Investigator Panel - composed of Professor Johannes Lammer1, Professor Anthony Watkinson2 and Professor Riccardo Lencioni3 - concluded that the PRECISION V results "� show that DC Bead is a better treatment than conventional TACE. An improved response with significantly frown toxicity is unusual for a young cancer therapy."
Biocompatibles
More info
